Nurlan Zharylkasynuly Akmyrzayev graduated from the Kazakh National Agrarian University in 2014 with a degree in veterinary medicine. He pursued postgraduate studies and, in 2016, earned a Master of Veterinary Science. Following this, he began his career as a junior researcher at the KazSRVI LLP.
Since 2021, he has been working at the "Research Institute of Biosafety and Biotechnology," where he actively contributes to the development of diagnostic tests and therapeutic-preventive preparations. Specifically, he has been involved in creating diagnostic tools, vaccines, and an anti-Moraxella ointment to combat infectious keratoconjunctivitis in cattle.
In addition, Nurlan Zharylkasynuly has been actively engaged in scientific projects and production processes, including:
Developing a recombinant vector vaccine based on the influenza virus for combating the COVID-19 coronavirus infection (2020–2022).
Participating in the production of the QazVac vaccine, as well as various poultry vaccines.
His scientific contributions include:
Over 30 published scientific works, including publications in both near and far-abroad countries.
Participation in scientific and practical conferences, delivering presentations on the results of his research.
Nurlan Zharylkasynuly Akmyrzayev graduated from the Kazakh National Agrarian University in 2014 with a degree in veterinary medicine. He pursued postgraduate studies and, in 2016, earned a Master of Veterinary Science. Following this, he began his career as a junior researcher at the KazSRVI LLP.
Since 2021, he has been working at the "Research Institute of Biosafety and Biotechnology," where he actively contributes to the development of diagnostic tests and therapeutic-preventive preparations. Specifically, he has been involved in creating diagnostic tools, vaccines, and an anti-Moraxella ointment to combat infectious keratoconjunctivitis in cattle.
In addition, Nurlan Zharylkasynuly has been actively engaged in scientific projects and production processes, including:
Developing a recombinant vector vaccine based on the influenza virus for combating the COVID-19 coronavirus infection (2020–2022).
Participating in the production of the QazVac vaccine, as well as various poultry vaccines.
His scientific contributions include:
Over 30 published scientific works, including publications in both near and far-abroad countries.
Participation in scientific and practical conferences, delivering presentations on the results of his research.